Success Metrics

Clinical Success Rate
88.2%

Based on 97 completed trials

Completion Rate
88%(97/110)
Active Trials
9(7%)
Results Posted
52%(50 trials)
Terminated
13(10%)

Phase Distribution

Ph phase_1
16
12%
Ph phase_4
27
20%
Ph early_phase_1
3
2%
Ph not_applicable
13
10%
Ph phase_2
45
34%
Ph phase_3
27
20%

Phase Distribution

19

Early Stage

45

Mid Stage

54

Late Stage

Phase Distribution131 total trials
Early Phase 1First-in-human
3(2.3%)
Phase 1Safety & dosage
16(12.2%)
Phase 2Efficacy & side effects
45(34.4%)
Phase 3Large-scale testing
27(20.6%)
Phase 4Post-market surveillance
27(20.6%)
N/ANon-phased studies
13(9.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.3%

97 of 115 finished

Non-Completion Rate

15.7%

18 ended early

Currently Active

9

trials recruiting

Total Trials

134

all time

Status Distribution
Active(9)
Completed(97)
Terminated(18)
Other(10)

Detailed Status

Completed97
Terminated13
unknown10
Recruiting8
Withdrawn5
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
134
Active
9
Success Rate
88.2%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (2.3%)
Phase 116 (12.2%)
Phase 245 (34.4%)
Phase 327 (20.6%)
Phase 427 (20.6%)
N/A13 (9.9%)

Trials by Status

completed9772%
active_not_recruiting11%
recruiting86%
terminated1310%
unknown107%
withdrawn54%

Recent Activity

Clinical Trials (134)

Showing 20 of 134 trialsScroll for more
NCT05536349Phase 2

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Recruiting
NCT07089875Phase 3

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Recruiting
NCT07089888Phase 3

A Study of Dotinurad Versus Allopurinol in Tophaceous Gout

Recruiting
NCT03150693Phase 3

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Recruiting
NCT04026776Early Phase 1

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

Recruiting
NCT03776656Phase 2

Evaluation of a Treatment With Allopurinol in Adenylosuccinate Lyase Deficiency

Completed
NCT04746989

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) Probenecid vs Allopurinol

Completed
NCT05888233Phase 2

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Recruiting
NCT05818085Phase 2

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

Completed
NCT04875702Phase 4

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Recruiting
NCT07177898Not Applicable

ALLOPURINOL AND LISINOPRIL FOR DIABETIC KIDNEY PROTECTION: A COMPARATIVE STUDY IN NORMOURICEMIC TYPE 2 DIABETICS

Completed
NCT05586971Phase 3

Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Completed
NCT06276556Phase 2

Extension Study of ABP-671 in Participants With Gout

Terminated
NCT02953509Phase 1

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Terminated
NCT05665699Phase 2

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Active Not Recruiting
NCT05601271Not Applicable

Effect of Allopurinol on Markers of Mineral and Bone Metabolism

Completed
NCT06056570Phase 1

Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia

Completed
NCT04956432Phase 3

A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Completed
NCT05049863Phase 1

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Terminated
NCT04217421Phase 3

Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
134